BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Files An 8-K Results of Operations and Financial Condition

On April 25, 2019, Bristol-Myers Squibb Company (the Company) issued a press release (the Earnings Press Release) announcing its financial results for the first quarter of 2019. A copy of the Earnings Press Release is furnished to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. Also furnished to this Item 2.02 as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein in its entirety is certain supplemental information posted on the Companys website at www.bms.com.

(d) Exhibits

The following exhibits are furnished as part of this Current Report on Form 8-K:

EXHIBIT INDEX

BRISTOL MYERS SQUIBB CO Exhibit
EX-99.1 2 q12019ex991.htm PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED APRIL 25,…
To view the full exhibit click here

About BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP)

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.